Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

ClinicalTrials.gov ID: NCT01876368

Public ClinicalTrials.gov record NCT01876368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan

Study identification

NCT ID
NCT01876368
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
376 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2013
Primary completion
Jul 31, 2014
Completion
Jul 31, 2014
Last update posted
Dec 6, 2015

2013 – 2014

United States locations

U.S. sites
22
U.S. states
13
U.S. cities
21
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35294-2041
Novartis Investigative Site Fair Oaks California 95628
Novartis Investigative Site Hawaiian Gardens California 90716
Novartis Investigative Site Long Beach California 90806
Novartis Investigative Site Los Angeles California 90057
Novartis Investigative Site Orangevale California 95662
Novartis Investigative Site Westlake Village California 91361
Novartis Investigative Site Denver Colorado 80206
Novartis Investigative Site Atlanta Georgia 30308
Novartis Investigative Site Conyers Georgia 30094
Novartis Investigative Site Chicago Illinois 60607
Novartis Investigative Site Chicago Illinois 60610
Novartis Investigative Site Topeka Kansas 66606
Novartis Investigative Site Edina Minnesota 55435
Novartis Investigative Site Belzoni Mississippi 39038
Novartis Investigative Site Jackson Mississippi 39209
Novartis Investigative Site New York New York 10708
Novartis Investigative Site Cincinnati Ohio 45246
Novartis Investigative Site Oregon City Oregon 97045
Novartis Investigative Site Portland Oregon 97225
Novartis Investigative Site Varnville South Carolina 29944
Novartis Investigative Site Richmond Virginia 23294

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01876368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 6, 2015 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01876368 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →